Search

Your search keyword '"Faden, Justin"' showing total 40 results
Start Over Author "Faden, Justin"
40 results on '"Faden, Justin"'

4. Efficacy of HP-3070, A Once-Daily Asenapine Transdermal System, in the Treatment of Adults with Schizophrenia: A PANSS Five-Factor Analysis

Author

Citrome,Leslie, Castelli,Mariacristina, Hasebe,Masami, Terahara,Takaaki, Faden,Justin, Komaroff,Marina, Citrome,Leslie, Castelli,Mariacristina, Hasebe,Masami, Terahara,Takaaki, Faden,Justin, and Komaroff,Marina

Abstract

Leslie Citrome,1 Mariacristina Castelli,2 Masami Hasebe,3 Takaaki Terahara,3 Justin Faden,4 Marina Komaroff2 1Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA; 2Product Development, Noven Pharmaceuticals, Inc, Jersey City, NJ, USA; 3Hisamitsu Pharmaceutical Co., Inc, Tokyo, Japan; 4Department of Psychiatry, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USACorrespondence: Leslie Citrome, Department of Psychiatry and Behavioral Sciences, New York Medical College, 40 Sunshine Cottage Road, Valhalla, NY, 10595, USA, Tel +1 845-362-2081, Email nntman@gmail.comIntroduction: HP-3070, a once-daily asenapine transdermal system, is the first antipsychotic “patch” formulation FDA approved for adults with schizophrenia. Positive and Negative Syndrome Scale (PANSS) score items can be grouped into a five-factor structure to describe specific schizophrenia symptom domains. This post hoc analysis of data from a pivotal study evaluated HP-3070’s efficacy by examining these factors.Methods: In a phase 3 study, adults with an acute exacerbation of schizophrenia were randomized to six weeks of treatment with HP-3070 3.8mg/24h, 7.6mg/24h, or placebo. An analysis was performed using the five PANSS factor domains (negative symptoms, positive symptoms, disorganized thought, uncontrolled hostility/excitement, anxiety/depression). Mixed-model repeated-measures (MMRM) analysis included change from baseline (CFB) in PANSS factor score as the repeated dependent variable, with country, treatment, visit, treatment by visit interaction, and baseline PANSS score as covariates.Results: The analysis included 607 patients. Treatment with HP-3070 3.8mg/24h resulted in a statistically significant LS mean CFB (improvement) vs placebo at Weeks 4– 6 for all domains except for anxiety/depression, where a numerical difference was observed in favor of active treatments. Among the domains, the positive symptom factor demonstrated the

Published
2024

5. An overview of the currently available and emerging long-acting formulations of risperidone for schizophrenia and bipolar disorder.

Author

Faden, Justin, Ramirez, Camila, Martinez, Vanessa, and Citrome, Leslie

Abstract

Long-acting injectable (LAI) antipsychotic medications can help improve treatment adherence in patients with schizophrenia and bipolar disorder. Despite this, they are underutilized. In 2003, intramuscular risperidone became the first available LAI atypical antipsychotic medication, and since then, a number of competing long-acting risperidone formulations have been brought to market, with additional options under active development. These include intramuscular, subcutaneous, long-acting oral, and implantable formulations. This review summarizes currently available and emerging long-acting risperidone formulations, including efficacy and safety data, and practical considerations aimed to help prescribers distinguish one formulation from another. There is an expanding number of currently available LAI antipsychotic medications giving patients and providers an opportunity to personalize and individualize care. Rates of adherence to treatment in patients with schizophrenia and bipolar disorder are low, and individualizing care can help improve this. The risperidone LAI treatment landscape includes five options approved by the U.S. Food and Drug Administration, with others under clinical development. These options differ in regard to mode of administration, approved indications, available dose strengths, injection intervals, needle size, injection volume, storage, and other variables. Prescribers should be familiar with these differing options to help patients find the best fit for their individual needs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions

Author

Kolli,Priyanka, Kelley,Grace, Rosales,Marianela, Faden,Justin, Serdenes,Ryan, Kolli,Priyanka, Kelley,Grace, Rosales,Marianela, Faden,Justin, and Serdenes,Ryan

Abstract

Priyanka Kolli,1 Grace Kelley,1 Marianela Rosales,2 Justin Faden,1 Ryan Serdenes3 1Department of Psychiatry, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA; 2Department of Psychiatry and Human Behavior, Thomas Jefferson University Hospital, Philadelphia, PA, USA; 3Department of Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, USACorrespondence: Ryan Serdenes, Email rserdenes@gmail.comAbstract: Olanzapine is one of the most widely used antipsychotics since its initial approval by the US Food and Drug Administration in 1996 and has undergone extensive pharmacokinetic study. Despite being utilized in clinical psychiatry for decades, there remain questions regarding the variety of available formulations, the utility of therapeutic drug monitoring, altered kinetic properties in special populations/medical illnesses, the use of high-dose olanzapine, and drug interactions, among many others. We performed a narrative literature review of olanzapine pharmacokinetics in June 2023 using the US National Library of Medicine’s PubMed.gov resource (https://www.ncbi.nlm.nih.gov/pubmed) and Google Scholar. Herein, we review clinically relevant aspects of olanzapine pharmacokinetic data while highlighting knowledge gaps and potential areas of future study.Keywords: olanzapine, pharmacokinetics, drug-drug interactions, pharmacodynamics, clinical psychopharmacology

Published
2023

19. Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults

Author

Faden,Justin and Citrome,Leslie

Subjects
Neuropsychiatric Disease and Treatment, mental disorders
Abstract

Justin Faden,1 Leslie Citrome21Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19125, USA; 2Psychiatry & Behavioral Sciences, New York Medical College, Valhalla, NY 10595, USAAbstract: Agitation is a common and serious symptom of bipolar mania and schizophrenia, and can be defined as excessive motor and verbal activity. If left unrecognized and untreated, agitation can evolve into aggression, resulting in potential patient and staff injury. An ideal treatment for agitation would have a rapid onset, cause calmness without sedation, and be tolerable, efficacious, and non-coercive, while managing the underlying condition. A novel approach for the treatment of agitation is inhaled loxapine. Inhaled loxapine is rapidly absorbed into the systemic circulation through the alveoli, resulting in a near immediate onset of action. The efficacy of inhaled loxapine was established in an extensive clinical development program that included persons with schizophrenia and bipolar mania. Additionally, inhaled loxapine has comparable efficacy to intramuscular ziprasidone, olanzapine, haloperidol, aripiprazole, and lorazepam, with the added benefit of being non-painful and non-traumatizing. Inhaled loxapine carries a bolded black box warning for bronchospasm, and as a result, in the US, requires enrollment in a Risk Evaluation and Mitigation Strategy program, and is contraindicated in those with pulmonary disease. Additionally, the use of inhaled loxapine can be associated with dysgeusia and throat irritation. Inhaled loxapine requires some degree of patient cooperation, and therefore may not be appropriate for all agitated patients.Keywords: inhaled loxapine, agitation, schizophrenia, bipolar disorder, mania, antipsychotic

Published
2019

23. Delusional Disorder, Erotomanic Type, Exacerbated by Social Media Use

Author

Faden, Justin, Levin, Jonathan, Mistry, Ronak, and Wang, Jessica

Subjects
Article Subject
Abstract

Erotomania is an uncommon form of delusional disorder in which an individual has an unfounded belief that another is in love with him. Previous case reports have shown that social media networks may play a role in worsening delusional beliefs. We report the case of a 24-year-old male college student that utilized social media to stalk a female college student, resulting in his suspension from school and hospitalization. The student was diagnosed with delusional disorder, erotomanic type, and started on risperidone. He showed little improvement and was transferred to another facility. This is the first identified case of social media triggering or exacerbating delusional disorder. We recommend increasing education on the ramifications of sharing personal information on social media.

Published
2017
Full Text
View/download PDF

26. Does antipsychotic combination therapy reduce the risk of hospitalization in schizophrenia?

Author

Faden, Justin, Kiryankova-Dalseth, Natasha, Barghini, Ruby, and Citrome, Leslie

Abstract

ABSTRACTIntroduction: Despite treatment with antipsychotic medication, approximately 1/3 of individuals with schizophrenia will fail to have an adequate response. To treat these patients, a commonly utilized approach is antipsychotic combination therapy. Antipsychotic combination therapy is controversial with mixed efficacy and tolerability results. It is also unclear if antipsychotic combination therapy reduces or increases the risk of psychiatric hospitalization.Areas Covered: The authors review the prevalence, efficacy and tolerability concerns, and rationale behind antipsychotic combination therapy. Evidence comparing antipsychotic monotherapy vs polypharmacy using hospitalization as an outcome measure is summarized.Expert opinion: Psychiatric rehospitalization is a useful measure of treatment effectiveness, incorporating aspects of treatment efficacy and tolerability. The evidence comparing the impact of antipsychotic monotherapy vs combination therapy on rehospitalization is mixed. Evidence is primarily retrospective in nature, and there is high heterogeneity between studies, which could partially explain the mixed results. There is likely a subset of patients for whom antipsychotic combination therapy reduces the risk of hospitalization greater than antipsychotic monotherapy. Patients should be treated individually taking into account their specific pattern of response.

Published
2021
Full Text
View/download PDF

29. Resistance is not futile: treatment-refractory schizophrenia – overview, evaluation and treatment

Author

Faden, Justin and Citrome, Leslie

Abstract

ABSTRACTIntroduction: Schizophrenia is a debilitating condition with three main symptom domains: positive, negative, and cognitive. Approximately one-third of persons with schizophrenia will fail to respond to treatment. Growing evidence suggests that treatment-resistant (refractory) schizophrenia (TRS) may be a distinct condition from treatment-respondent schizophrenia. There is limited evidence on effective treatments for TRS, and a lack of standardized diagnostic criteria for TRS has hampered research.Areas covered: A literature search was conducted using Pubmed.gov and the EMBASE literature database. The authors discuss the pragmatic definitions of TRS and review treatments consisting of antipsychotic monotherapy and augmentation strategies.Expert opinion: Currently available first-line antipsychotic medications are generally effective at treating the positive symptoms of schizophrenia, leaving residual negative and cognitive symptoms. Before diagnosing TRS, rule out any pharmacodynamic or pharmacokinetic failures. Most evidence supports clozapine as having the most efficacy for TRS. If clozapine is used, it should be optimized, and serum levels should be at least 350–420 ng/ml. If clozapine is unable to be tolerated, some evidence suggests olanzapine at dosages up to 40mg/day can be useful. Augmentation strategies have weak evidence. Tailoring treatment to the specific domain is the preferred approach, and the use of a structured assessment/outcome measure is encouraged.

Published
2019
Full Text
View/download PDF

34. Empathy in Osteopathic Medical Students: A Cross-Sectional Analysis

Author

Kimmelman, Marilyn, Giacobbe, Jackie, Faden, Justin, Kumar, Geetha, Pinckney, Charlyene C., and Steer, Robert

Abstract

Context:Empathy is fundamental to patient care. Research studies of allopathic medical students have found a statistically significant decrease in empathy levels by the third year. Levels of empathy in osteopathic medical students have not been evaluated to determine whether a similar decline occurs in this group.

Published
2012
Full Text
View/download PDF

38. Self-inflicted Abdominal Trauma.

Author

Lewis M and Faden J

Subjects
Abdominal Injuries psychology, Factitious Disorders psychology, Female, Humans, Middle Aged, Abdominal Injuries diagnostic imaging, Borderline Personality Disorder psychology, Self-Injurious Behavior
Published
2017
Full Text
View/download PDF

40. Empathy in osteopathic medical students: a cross-sectional analysis.

Author

Kimmelman M, Giacobbe J, Faden J, Kumar G, Pinckney CC, and Steer R

Subjects
Adult, Analysis of Variance, Chi-Square Distribution, Cross-Sectional Studies, Educational Measurement, Female, Humans, Male, Pennsylvania, Psychometrics, Self Report, Sex Factors, Surveys and Questionnaires, Young Adult, Communication, Empathy, Osteopathic Medicine methods, Patient Care psychology, Physician-Patient Relations, Students, Medical psychology
Abstract

Context: Empathy is fundamental to patient care. Research studies of allopathic medical students have found a statistically significant decrease in empathy levels by the third year. Levels of empathy in osteopathic medical students have not been evaluated to determine whether a similar decline occurs in this group., Objectives: To determine whether there were differences according to year of schooling in mean levels of empathy among osteopathic medical students, as assessed with the Jefferson Scale of Physician Empathy-Student Version (JSPE-S), and, secondarily, to compare these measures of empathy in osteopathic medical students with those reported elsewhere for allopathic medical students., Methods: The JSPE-S was distributed to students during regularly scheduled classes at the end of the academic year at the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine in Stratford. Responses were anonymous. Data were analyzed by year in osteopathic medical school, sex, planned specialty, and ethnicity. Scores were compared with those of allopathic medical students reported elsewhere., Results: Of the 415 respondents, 405 (98%) returned questionnaires with complete information, including 187 men (46%) and 218 women (54%). Of these respondents, 208 (51%) were white, 124 (31%) were Asian, and 73 (18%) were of another ethnicity. There were no statistically significant differences by year of schooling in respondents' sex, ethnicity, or specialty orientation and no statistically significant differences by year of schooling in the mean JSPE-S scores., Conclusion: Levels of empathy in osteopathic medical students were not found to decrease significantly by year of schooling, as reported in other studies for allopathic medical students. However, mean JSPE-S scores for first- and second-year osteopathic medical students were lower than those for first- and second-year allopathic medical students.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results